Alexander Hardy, Ceo of Genentech, a member of the Roche Group, has decided to leave the company and will step down from his role on November 1st 2023.
Hardy first joined Genentech in 2005 and held several senior management positions before assuming the role of CEO in March 2019.
Ashley Magargee, head of U.S. Commercial Portfolio, who has been serving as ad interim CEO during Alexander's recent sabbatical, will continue in this role until a successor is announced.
Magargee joined Genentech in 2004 and previously held senior management positions at Roche and Genentech in lifecycle management, digital customer experience, market access and was also General Manager in Singapore.